GNOM Global X Genomics & Biotechnology ETF Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
14:52
Aug 25
Aug 25
Genome sector with AI could run higher
Author suggests a bullish breakout for the genome ETF, arguing the sector combines biotech with AI and is underappreciated, with significant upside potential by 2030.
MED
15:38
Aug 19
Aug 19
AI integration drives long-term genomics sector upside.
Author is bullish on the genomics ETF, arguing the sector is still in its early stages and will benefit significantly from AI integration.
MED
19:03
Aug 10
Aug 10
GNOM is making another local all-time high while the author previously argued genome.
GNOM is making another local all-time high while the author previously argued genome and biotech stocks should be much higher by 2030 with AI tailwinds.
LOW
16:39
Jul 01
Jul 01
Buy $GNOM on the thesis that AI unlocks genomics breakthroughs.
Buy $GNOM on the thesis that AI unlocks genomics breakthroughs, with a catalyst from a major disease‑cure news story, supported by recent 20% momentum.
MED
22:42
Jun 27
Jun 27
Buy genomics ETF as part of healthcare/biotech midterm H2 seasonal rotation.
Buy genomics ETF as part of healthcare/biotech midterm H2 seasonal rotation; lowest-conviction leg given GNOM's thin liquidity relative to XBI/ARKG.
MED
17:15
Jun 23
Jun 23
Author prefers single tickers over ETFs like GNOM or ARKG for broad exposure.
Author prefers single tickers over ETFs like GNOM or ARKG for broad exposure, offering no directional view.
LOW
14:19
Jun 23
Jun 23
Long GNOM based on near all-time lows and forward-looking outperformance potential vs other.
Long GNOM based on near all-time lows and forward-looking outperformance potential vs other ETFs near highs.
MED
20:44
Jun 22
Jun 22
Buy GNOM for long-term outperformance as AI makes genome stocks sensible.
Buy GNOM for long-term outperformance as AI makes genome stocks sensible, with the ETF near ATLs offering upside vs S&P near ATHs.
HIGH
06:01
Jun 18
Jun 18
GNOM has explicit 100 price target from current 50 level.
Author states GNOM is at 50 with a 100 target, which is an explicit forward bullish price-target call.
About GNOM Analyst Coverage
Buzzberg tracks GNOM (Global X Genomics & Biotechnology ETF) across 2 sources. 7 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (78%). 9 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: incomesharks, CryptoCondom.